New antibacterial agents for treating infections caused by multi-drug resistant Gram-negative bacteria

Bibliography

• Micek ST. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2007;45(Suppl 3):S184-90
   PubMed Web of Science ®Google Scholar
• Chopra I, Schofield C, Everett M, et al. Treatment of healthcare-associated infections caused by Gram-negative bacteria: a consensus statement. Lancet Infect Dis 2008;8:133-9
   PubMed Web of Science ®Google Scholar
• Rice LB. Unmet medical needs in antibacterial therapy. Biochem Pharmacol 2006;71:991-5
   PubMed Web of Science ®Google Scholar
• Talbot GH, Bradley J, Edwards JE Jr, et al. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006;42:657-68
   PubMed Web of Science ®Google Scholar
• Falagas ME, Bliziotis IA. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Agents 2007;29:630-6
   PubMed Web of Science ®Google Scholar
• Thomson JM, Bonomo RA. The threat of antibiotic resistance in Gram-negative pathogenic bacteria: beta-lactams in peril! Curr Opin Microbiol 2005;8:518-24
   Google Scholar
• Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005;40:1333-41
   PubMed Web of Science ®Google Scholar
• Rice LB. Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2006;43:S100-5
   PubMed Web of Science ®Google Scholar
• Livermore DM. Introduction: the challenge of multiresistance. Int J Antimicrob Agents 2007;29(Suppl 3):S1-7
   PubMed Web of Science ®Google Scholar
• O'Neill AJ, Chopra I. Preclinical evaluation of novel antibacterial agents by microbiological and molecular techniques. Expert Opin Investig Drugs 2004;13:1045-63
   PubMed Web of Science ®Google Scholar
• Projan SJ. (Genome) size matters. Antimicrob Agents Chemother 2007;51:1133-4
   PubMed Web of Science ®Google Scholar
• Oliver A, Canton R, Campo P, et al. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000;288:1251-4
   PubMed Web of Science ®Google Scholar
• Gu B, Tong M, Zhao W, et al. Prevalence and characterization of class I integrons among Pseudomonas aeruginosa and Acinetobacter baumannii isolates from patients in Nanjing, China. J Clin Microbiol 2007;45:241-3
   PubMed Web of Science ®Google Scholar
• Metzgar D, Bacher JM, Pezo V, et al. Acinetobacter sp. ADP1: an ideal model organism for genetic analysis and genome engineering. Nucleic Acids Res 2004;32:5780-90
   PubMed Web of Science ®Google Scholar
• Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007;6:29-40
   PubMed Web of Science ®Google Scholar
• Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, 27 – 30 September 2006
   Google Scholar
• Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, 17 – 20 September 2007
   Google Scholar
• Projan SJ, Shlaes DM. Antibacterial drug discovery: is it all downhill from here? Clin Microbiol Infect 2004;10(Suppl 4):18-22
   PubMed Web of Science ®Google Scholar
• Fox JL. The business of developing antibacterials. Nat Biotechnol 2006;24:1521-8
   PubMed Web of Science ®Google Scholar
• Livermore DM, Woodford N. The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol 2006;14:413-20
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007;67:1027-52
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004;48:3086-92
   PubMed Web of Science ®Google Scholar
• Takeda S, Nakai T, Wakai Y, et al. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2007;51:826-30
   PubMed Web of Science ®Google Scholar
• Levasseur P, Girard AM, Delachaume C, et al. NXL104, a novel β-lactamase inhibitor, restores the bactericidal activity of ceftazidime against ESBL and AmpC producing strains of Enterobacteriaceae. 46th Interscience Conference on Antimicrobial Agents & Chemotherapy; 2006. Abstract F-127
   Google Scholar
• Novexel. Drug discovery and development. Available at: http://www.novexel.com/ [Last accessed 30 January 2008]
   Google Scholar
• Livermore DM. Tigecycline: what is it, and where should it be used? J Antimicrob Chemother 2005;56:611-4
   PubMed Web of Science ®Google Scholar
• Pachon-Ibanez ME, Jimenez-Mejias ME, Pichardo C, et al. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 2004;48:4479-81
   PubMed Web of Science ®Google Scholar
• Dean CR, Visalli MA, Projan SJ, et al. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 2003;47:972-8
   PubMed Web of Science ®Google Scholar
• Peleg AY, Potoski BA, Rea R, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007;59:128-31
   PubMed Web of Science ®Google Scholar
• Daiichi Sankyo Europe. Available at: http://www.daiichi-sankyo.eu/site_eu/ [Last accessed 30 January 2008]
   Google Scholar
• Mesaros N, Nordmann P, Plesiat P, et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 2007;13:560-78
   PubMed Web of Science ®Google Scholar
• Miyazaki S, Matsumoto T, Tateda K, Yamaguchi K. In vitro and in vivo evaluation of DU6859a, a new fluoroquinolone, among injectable antibacterials tested against clinical isolates. J Infect Chemother 1996;2:148-55
   Google Scholar
• Brisse S, Milatovic D, Fluit AC, et al. Molecular surveillance of European quinolone-resistant clinical isolates of Pseudomonas aeruginosa and Acinetobacter spp. using automated ribotyping. J Clin Microbiol 2000;38:3636-45
   PubMed Web of Science ®Google Scholar
• Biovertis website. Available at: http://www.biovertis.com/
   Google Scholar
• Spiderbiotech website. Available at: http://www.spiderbiotech.com/
   Google Scholar
• PepTx website. Available at: http://www.peptx.com/
   Google Scholar
• PolyMedix website. Available at: http://www.polymedix.com/
   Google Scholar
• Mutabilis website. Available at: http://www.mutabilis.fr/
   Google Scholar
• Escaich S, Moreau F, Floquet S, et al. Discovery of new Gram-negative antivirulence drugs 2: characterization of novel E. coli RfaE inhibitors. 46th Interscience Conference on Antimicrobial Agents & Chemotherapy 2006. Abstract F2-496
   Google Scholar
• Denis A, Moreau F, Genevard J, et al. Discovery of new Gram-negative antivirulence drugs 1: structure and properties of novel E. coli WaaC inhibitors. 46th Interscience Conference on Antimicrobial Agents & Chemotherapy, 2006. Abstract F2-1169
   Google Scholar
• Barrett JF. MC-207110 Daiichi Seiyaku/Microcide Pharmaceuticals. Curr Opin Investig Drugs 2001;2:212-5
   PubMedGoogle Scholar
• Lomovskaya O, Bostian KA. Practical applications and feasibility of efflux pump inhibitors in the clinic – a vision for applied use. Biochem Pharmacol 2006;71:910-8
   PubMed Web of Science ®Google Scholar
• Mpex Pharmaceuticals website. Available at: http://www.mpexpharma.com/
   Google Scholar
• Rahal JJ. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006;43:S95-9
   PubMed Web of Science ®Google Scholar
• Pankuch GA, Lin G, Seifert H, Appelbaum PC. Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Antimicrob Agents Chemother 2008;52(1):333-6
   Google Scholar
• Kaneko Y, Thoendel M, Olakanmi O, et al. The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity. J Clin Invest 2007;117:877-88
   PubMed Web of Science ®Google Scholar
• Kristiansen JE, Hendricks O, Delvin T, et al. Reversal of resistance in microorganisms by help of non-antibiotics. J Antimicrob Chemother 2007;59:1271-9
   PubMed Web of Science ®Google Scholar
• Wellcome Trust and GlaxoSmithKline announce partnership to target drug-resistant hospital infections, 30 April 2007. Available at: http://www.wellcome.ac.uk/doc_WTX037132.html
   Google Scholar
• Baquero F, Coast J, Frimodt-Moller N, et al. Antibiotic resistance. Brussels: Scientific and Technological Options Assessment (STOA), 2006
   Google Scholar
• Mahamoud A, Chevalier J, Alibert-Franco S, et al. Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy. J Antimicrob Chemother 2007;59:1223-9
   PubMed Web of Science ®Google Scholar
• Budzikiewicz H. Siderophore-antibiotic conjugates used as Trojan horses against Pseudomonas aeruginosa. Curr Top Med Chem 2001;1:73-82
   PubMedGoogle Scholar